Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution.

Qi QuanYixing WangFenghua WangDongsheng ZhangXiuxing ChenWen-Zhuo HeBei ZhangGuifang Guo

Published in: Current oncology (Toronto, Ont.) (2020)

In the first line treatment of UPC, our results suggest that nab-paclitaxel plus gemcitabine was associated with a higher DCR than mFOLFIRINOX or GEMOX, while all groups demonstrated similar OS, PFS and ORR.

Keyphrases

locally advanced
advanced non small cell lung cancer
rectal cancer
squamous cell carcinoma
radiation therapy
chemotherapy induced
liver metastases
metabolic syndrome
glycemic control